STUDY ON THE ACUTE AND SEMI-CHRONIC TOXICITY OF HUP A CAPSULE IN EXPERIMENTAL ANIMALS

Thị Hồng Hạnh Lê , Minh Trung Đỗ, Nam Trung Trịnh, Văn Huy Nguyễn, Văn Thư Nguyễn

Main Article Content

Abstract

Objectives: To evaluate the acute toxicity on Hup A soft capsules in mice and sub-chronic toxicity in rabbits. Methods: The acute toxicity was assessed in mice using the Litchfield - Wilcoxon method; the semi-chronic toxicity was assessed in rabbits according to the guidelines of the OECD and the Ministry of Health of Vietnam. The products used in this study were Hup A soft capsules, Enterprise standard. Results: After giving Hup A capsules (40.00 - 160.00 g/kg) to mice, we determined LD50 = 92.88 g/kg (79.59 - 108.39 g/kg). High dose batches of mice showed tremors, increased sweating, and then they died. With two dosage of 0.12 g/kg/24h and 0.36 g/kg/24h, rabbits were administered continuously during 42 days. The results showed that no impact was detected on some hematological parameters: Red blood cell count, white blood cell count, and hemoglobin content; indicators of liver and kidney function: AST, ALT enzyme activities, Cholesterol, Albumin, Total Bilirubin and Creatinine content, histopathology of liver and kidney cells were normal in experimental rabbits. Conclusion: Hup A capsules had LD50 = 92,88 g/kg (79,59 - 108,39 g/kg) in white mice and did not affect hematopoietic, liver, or kidney function of experimental rabbits after 42 days of study.

Article Details

References

1. Alzheimer’s Desease International. World Alzheimer report 2015.
2. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị một số rối loạn tâm thần thường gặp. Quyết định số 2058/QĐ-BYT, ngày 14/05/2020.
3. U Damar, R Gersner, J T Johnstone et al. Huperzine A as a neuroprotective and antiepileptic drug: A review of preclinical research. Expert Rep Neurother. 2016; 16(6):671-80.
4. Bộ Y tế. Hướng dẫn thử nghiệm tiền lâm sàng và lâm sàng thuốc đông y, thuốc từ dược liệu. Quyết định 141- QĐ- K2ĐT 27/10/2015.
5. Đỗ Trung Đàm. Phương pháp nghiên cứu độc tính cấp của thuốc. Nhà xuất bản Y học. Hà Nội. 2014.
6. OECD, Test No.407: Repeated Dose 28-day Oral Toxicity Study in Rodents, OECD Guidelines for the testing of Chemicals, Section 4: Health Efects. 2008.
7. Debasis Bagchi, Manashi Bagchi, Anand Swaroop et al. Huperzine A and Shankhapushpi in Brain Health. Phytopharmaceuticals for Brain Health. 2017:101-118.
8. Giang T Ha, Ryan K Wong, Yan Zhang. Huperzine aHs a potential treatment of Alzheimer’s disease: An assessment on chemistry, pharmacology, and clinical studies. Chemistry & Biodiversity. 2011; 8(7):1189-1204.
9. SS Xu, ZX Gao, Z Weng et al. Efficacy of tablet HuperzineA on memory, cognition, and behavior in Alzheimer’s disease. Zhonggou Yao Li Xue Bao. 1995; 16(5):391-395.
10. Lei Sheng, Yi Qu, Jing Yan et al. Population pharmacokinetic modeling and stimulation of huperzine A in elderly Chinese subjects. Acta Pharmacol Sin. 2016; 37(7):994-1001.